Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Goetz

Showing results (521-530 of 754) with videos related to

Pageof 76
Sort By:
Neurology|May 1, 1991
The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's diseaseP M Carvey, A McRae, T F Lint, et al.
Neurology. Clinical Practice|January 12, 2024
A Novel Home-Based Telerehabilitation Program Targeting Fall Prevention in Parkinson Disease: A Preliminary TrialMitra Afshari, Andrea V Hernandez, Jessica M Joyce, et al.
Neuroscience Letters|November 22, 1988
An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantationA McRae-Degueurce, H L Klawans, R D Penn, et al.
Clinical Neuropharmacology|July 15, 2004
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)C Warren Olanow, Philippe Damier, Christopher G Goetz, et al.
Molecular and Cellular Biology|July 22, 2009
The absence of caveolin-1 increases proliferation and anchorage- independent growth by a Rac-dependent, Erk-independent mechanismAna Cerezo, Marta C Guadamillas, Jacky G Goetz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Neurology|November 1, 1991
United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-upC G Goetz, G T Stebbins, H L Klawans, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2009
Determinants of quality of life in children with Gilles de la Tourette syndromeBryan A Bernard, Glenn T Stebbins, Sandra Siegel, et al.
The New England Journal of Medicine|September 25, 1999
Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's diseaseT B Freeman, D E Vawter, P E Leaverton, et al.
The New England Journal of Medicine|January 11, 1996
Prevalence of parkinsonian signs and associated mortality in a community population of older peopleD A Bennett, L A Beckett, A M Murray, et al.
Pageof 76

Showing results (521-530 of 754) with videos related to

Sort By:
Pageof 76
Neurology|May 1, 1991
The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's diseaseP M Carvey, A McRae, T F Lint, et al.
Neurology. Clinical Practice|January 12, 2024
A Novel Home-Based Telerehabilitation Program Targeting Fall Prevention in Parkinson Disease: A Preliminary TrialMitra Afshari, Andrea V Hernandez, Jessica M Joyce, et al.
Neuroscience Letters|November 22, 1988
An antibody in the CSF of Parkinson's disease patients disappears following adrenal medulla transplantationA McRae-Degueurce, H L Klawans, R D Penn, et al.
Clinical Neuropharmacology|July 15, 2004
Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study)C Warren Olanow, Philippe Damier, Christopher G Goetz, et al.
Molecular and Cellular Biology|July 22, 2009
The absence of caveolin-1 increases proliferation and anchorage- independent growth by a Rac-dependent, Erk-independent mechanismAna Cerezo, Marta C Guadamillas, Jacky G Goetz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 5, 2008
Placebo influences on dyskinesia in Parkinson's diseaseChristopher G Goetz, Eugene Laska, Christine Hicking, et al.
Neurology|November 1, 1991
United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-upC G Goetz, G T Stebbins, H L Klawans, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 24, 2009
Determinants of quality of life in children with Gilles de la Tourette syndromeBryan A Bernard, Glenn T Stebbins, Sandra Siegel, et al.
The New England Journal of Medicine|September 25, 1999
Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's diseaseT B Freeman, D E Vawter, P E Leaverton, et al.
The New England Journal of Medicine|January 11, 1996
Prevalence of parkinsonian signs and associated mortality in a community population of older peopleD A Bennett, L A Beckett, A M Murray, et al.
Pageof 76